Revision of the International Neuroblastoma Pathology Classification

BACKGROUND Ganglioneuroblastoma, nodular (GNBn) comprises one of the categories of peripheral neuroblastic tumors. All tumors in this category, according to the original International Neuroblastoma Pathology Classification, are classified into an unfavorable histology group. Subsequently, it has bee...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2003-11, Vol.98 (10), p.2274-2281
Hauptverfasser: Peuchmaur, Michel, d'Amore, Emanuele S. G., Joshi, Vijay V., Hata, Jun‐ichi, Roald, Borghild, Dehner, Louis P., Gerbing, Robert B., Stram, Daniel O., Lukens, John N., Matthay, Katherine K., Shimada, Hiroyuki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2281
container_issue 10
container_start_page 2274
container_title Cancer
container_volume 98
creator Peuchmaur, Michel
d'Amore, Emanuele S. G.
Joshi, Vijay V.
Hata, Jun‐ichi
Roald, Borghild
Dehner, Louis P.
Gerbing, Robert B.
Stram, Daniel O.
Lukens, John N.
Matthay, Katherine K.
Shimada, Hiroyuki
description BACKGROUND Ganglioneuroblastoma, nodular (GNBn) comprises one of the categories of peripheral neuroblastic tumors. All tumors in this category, according to the original International Neuroblastoma Pathology Classification, are classified into an unfavorable histology group. Subsequently, it has been reported that GNBn can be divided into two prognostic subsets, a favorable subset (FS) and an unfavorable subset (US). METHODS Histology slides from 70 patients who were enrolled in Children's Cancer Group studies 3881 and 3891 and who had a diagnosis of GNBn were reviewed jointly by the members of International Neuroblastoma Pathology Committee (INPC): 1) to confirm the diagnosis of GNBn, 2) to identify the FS and US by applying the same age‐linked criteria that were used to distinguish the favorable histology group and unfavorable histology group in conventional neuroblastoma tumors from the neuroblastomatous component of GNBn tumors, and 3) to verify the significant prognostic difference between these two subsets. The patients had been used in a previous study, and survival data for the patients were updated since the time of their last report. RESULTS The review clarified and illustrated morphologic characteristics of classical GNBn and it variants. The diagnosis of GNBn was confirmed in 67 of 70 patients. There were 22 patients with GNBn in the FS and 45 patients with GNBn in the US. The estimated survival differences between the FS and US patients with GNBn were statistically significant (8‐year event free survival rate: 86.1% vs. 32.2%; P = 0.0003; overall survival rate: 90.5% vs. 33.2%; P = 0.0003). CONCLUSIONS This study confirmed the recently defined prognostic subsets of GNBn. The INPC proposes to modify the International Neuroblastoma Pathology Classification by distinguishing the FS and the US among patients with GNBn tumors. Cancer 2003. © 2003 American Cancer Society. The International Neuroblastoma Pathology Committee (INPC) conducted a review of 70 tumors in the ganglioneuroblastoma, nodular (GNBn) category. After clearly defining morphologic characteristics of those tumors and completing a survival analysis, the INPC proposes to modify the International Neuroblastoma Pathology Classification for GNBn by distinguishing prognostic subsets, favorable and unfavorable, in this category.
doi_str_mv 10.1002/cncr.11773
format Article
fullrecord <record><control><sourceid>wiley</sourceid><recordid>TN_cdi_wiley_primary_10_1002_cncr_11773_CNCR11773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR11773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1853-60c86840fd81fc5e359a96243001b3c4d5d103bf25963f68149a691eaea19a8f3</originalsourceid><addsrcrecordid>eNotj81KxDAUhYMoWEc3PkFeoOO9TZMmS6l_A8Mog4K7cpsmTqXTSlOVvv10qqvzw-HAx9g1whIBkhvb2n6JmGXihEUIJosB0-SURQCgY5mK93N2EcLnFLNEiojdbd1PHequ5Z3nw87xVTu4vqVhqqjhG_fdd2VDYej2xF9o2HVN9zHyfKpC7Ws7Dy_ZmacmuKt_XbC3h_vX_ClePz-u8tt1bFFLESuwWukUfKXRW-mENGRUkgoALIVNK1khiNIn0ijhlcbUkDLoyBEa0l4sGP79_taNG4uvvt5TPxYIxRG-OMIXM3yRb_Lt7MQBLmVPxw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Revision of the International Neuroblastoma Pathology Classification</title><source>Wiley Online Library Free Content</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Peuchmaur, Michel ; d'Amore, Emanuele S. G. ; Joshi, Vijay V. ; Hata, Jun‐ichi ; Roald, Borghild ; Dehner, Louis P. ; Gerbing, Robert B. ; Stram, Daniel O. ; Lukens, John N. ; Matthay, Katherine K. ; Shimada, Hiroyuki</creator><creatorcontrib>Peuchmaur, Michel ; d'Amore, Emanuele S. G. ; Joshi, Vijay V. ; Hata, Jun‐ichi ; Roald, Borghild ; Dehner, Louis P. ; Gerbing, Robert B. ; Stram, Daniel O. ; Lukens, John N. ; Matthay, Katherine K. ; Shimada, Hiroyuki</creatorcontrib><description>BACKGROUND Ganglioneuroblastoma, nodular (GNBn) comprises one of the categories of peripheral neuroblastic tumors. All tumors in this category, according to the original International Neuroblastoma Pathology Classification, are classified into an unfavorable histology group. Subsequently, it has been reported that GNBn can be divided into two prognostic subsets, a favorable subset (FS) and an unfavorable subset (US). METHODS Histology slides from 70 patients who were enrolled in Children's Cancer Group studies 3881 and 3891 and who had a diagnosis of GNBn were reviewed jointly by the members of International Neuroblastoma Pathology Committee (INPC): 1) to confirm the diagnosis of GNBn, 2) to identify the FS and US by applying the same age‐linked criteria that were used to distinguish the favorable histology group and unfavorable histology group in conventional neuroblastoma tumors from the neuroblastomatous component of GNBn tumors, and 3) to verify the significant prognostic difference between these two subsets. The patients had been used in a previous study, and survival data for the patients were updated since the time of their last report. RESULTS The review clarified and illustrated morphologic characteristics of classical GNBn and it variants. The diagnosis of GNBn was confirmed in 67 of 70 patients. There were 22 patients with GNBn in the FS and 45 patients with GNBn in the US. The estimated survival differences between the FS and US patients with GNBn were statistically significant (8‐year event free survival rate: 86.1% vs. 32.2%; P = 0.0003; overall survival rate: 90.5% vs. 33.2%; P = 0.0003). CONCLUSIONS This study confirmed the recently defined prognostic subsets of GNBn. The INPC proposes to modify the International Neuroblastoma Pathology Classification by distinguishing the FS and the US among patients with GNBn tumors. Cancer 2003. © 2003 American Cancer Society. The International Neuroblastoma Pathology Committee (INPC) conducted a review of 70 tumors in the ganglioneuroblastoma, nodular (GNBn) category. After clearly defining morphologic characteristics of those tumors and completing a survival analysis, the INPC proposes to modify the International Neuroblastoma Pathology Classification for GNBn by distinguishing prognostic subsets, favorable and unfavorable, in this category.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.11773</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>ganglioneuroblastoma ; histology ; international classification ; International Neuroblastoma Pathology Committee ; nodular ; peripheral neuroblastic tumors ; prognostic subsets</subject><ispartof>Cancer, 2003-11, Vol.98 (10), p.2274-2281</ispartof><rights>Copyright © 2003 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1853-60c86840fd81fc5e359a96243001b3c4d5d103bf25963f68149a691eaea19a8f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.11773$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.11773$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids></links><search><creatorcontrib>Peuchmaur, Michel</creatorcontrib><creatorcontrib>d'Amore, Emanuele S. G.</creatorcontrib><creatorcontrib>Joshi, Vijay V.</creatorcontrib><creatorcontrib>Hata, Jun‐ichi</creatorcontrib><creatorcontrib>Roald, Borghild</creatorcontrib><creatorcontrib>Dehner, Louis P.</creatorcontrib><creatorcontrib>Gerbing, Robert B.</creatorcontrib><creatorcontrib>Stram, Daniel O.</creatorcontrib><creatorcontrib>Lukens, John N.</creatorcontrib><creatorcontrib>Matthay, Katherine K.</creatorcontrib><creatorcontrib>Shimada, Hiroyuki</creatorcontrib><title>Revision of the International Neuroblastoma Pathology Classification</title><title>Cancer</title><description>BACKGROUND Ganglioneuroblastoma, nodular (GNBn) comprises one of the categories of peripheral neuroblastic tumors. All tumors in this category, according to the original International Neuroblastoma Pathology Classification, are classified into an unfavorable histology group. Subsequently, it has been reported that GNBn can be divided into two prognostic subsets, a favorable subset (FS) and an unfavorable subset (US). METHODS Histology slides from 70 patients who were enrolled in Children's Cancer Group studies 3881 and 3891 and who had a diagnosis of GNBn were reviewed jointly by the members of International Neuroblastoma Pathology Committee (INPC): 1) to confirm the diagnosis of GNBn, 2) to identify the FS and US by applying the same age‐linked criteria that were used to distinguish the favorable histology group and unfavorable histology group in conventional neuroblastoma tumors from the neuroblastomatous component of GNBn tumors, and 3) to verify the significant prognostic difference between these two subsets. The patients had been used in a previous study, and survival data for the patients were updated since the time of their last report. RESULTS The review clarified and illustrated morphologic characteristics of classical GNBn and it variants. The diagnosis of GNBn was confirmed in 67 of 70 patients. There were 22 patients with GNBn in the FS and 45 patients with GNBn in the US. The estimated survival differences between the FS and US patients with GNBn were statistically significant (8‐year event free survival rate: 86.1% vs. 32.2%; P = 0.0003; overall survival rate: 90.5% vs. 33.2%; P = 0.0003). CONCLUSIONS This study confirmed the recently defined prognostic subsets of GNBn. The INPC proposes to modify the International Neuroblastoma Pathology Classification by distinguishing the FS and the US among patients with GNBn tumors. Cancer 2003. © 2003 American Cancer Society. The International Neuroblastoma Pathology Committee (INPC) conducted a review of 70 tumors in the ganglioneuroblastoma, nodular (GNBn) category. After clearly defining morphologic characteristics of those tumors and completing a survival analysis, the INPC proposes to modify the International Neuroblastoma Pathology Classification for GNBn by distinguishing prognostic subsets, favorable and unfavorable, in this category.</description><subject>ganglioneuroblastoma</subject><subject>histology</subject><subject>international classification</subject><subject>International Neuroblastoma Pathology Committee</subject><subject>nodular</subject><subject>peripheral neuroblastic tumors</subject><subject>prognostic subsets</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNotj81KxDAUhYMoWEc3PkFeoOO9TZMmS6l_A8Mog4K7cpsmTqXTSlOVvv10qqvzw-HAx9g1whIBkhvb2n6JmGXihEUIJosB0-SURQCgY5mK93N2EcLnFLNEiojdbd1PHequ5Z3nw87xVTu4vqVhqqjhG_fdd2VDYej2xF9o2HVN9zHyfKpC7Ws7Dy_ZmacmuKt_XbC3h_vX_ClePz-u8tt1bFFLESuwWukUfKXRW-mENGRUkgoALIVNK1khiNIn0ijhlcbUkDLoyBEa0l4sGP79_taNG4uvvt5TPxYIxRG-OMIXM3yRb_Lt7MQBLmVPxw</recordid><startdate>20031115</startdate><enddate>20031115</enddate><creator>Peuchmaur, Michel</creator><creator>d'Amore, Emanuele S. G.</creator><creator>Joshi, Vijay V.</creator><creator>Hata, Jun‐ichi</creator><creator>Roald, Borghild</creator><creator>Dehner, Louis P.</creator><creator>Gerbing, Robert B.</creator><creator>Stram, Daniel O.</creator><creator>Lukens, John N.</creator><creator>Matthay, Katherine K.</creator><creator>Shimada, Hiroyuki</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope/></search><sort><creationdate>20031115</creationdate><title>Revision of the International Neuroblastoma Pathology Classification</title><author>Peuchmaur, Michel ; d'Amore, Emanuele S. G. ; Joshi, Vijay V. ; Hata, Jun‐ichi ; Roald, Borghild ; Dehner, Louis P. ; Gerbing, Robert B. ; Stram, Daniel O. ; Lukens, John N. ; Matthay, Katherine K. ; Shimada, Hiroyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1853-60c86840fd81fc5e359a96243001b3c4d5d103bf25963f68149a691eaea19a8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>ganglioneuroblastoma</topic><topic>histology</topic><topic>international classification</topic><topic>International Neuroblastoma Pathology Committee</topic><topic>nodular</topic><topic>peripheral neuroblastic tumors</topic><topic>prognostic subsets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peuchmaur, Michel</creatorcontrib><creatorcontrib>d'Amore, Emanuele S. G.</creatorcontrib><creatorcontrib>Joshi, Vijay V.</creatorcontrib><creatorcontrib>Hata, Jun‐ichi</creatorcontrib><creatorcontrib>Roald, Borghild</creatorcontrib><creatorcontrib>Dehner, Louis P.</creatorcontrib><creatorcontrib>Gerbing, Robert B.</creatorcontrib><creatorcontrib>Stram, Daniel O.</creatorcontrib><creatorcontrib>Lukens, John N.</creatorcontrib><creatorcontrib>Matthay, Katherine K.</creatorcontrib><creatorcontrib>Shimada, Hiroyuki</creatorcontrib><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peuchmaur, Michel</au><au>d'Amore, Emanuele S. G.</au><au>Joshi, Vijay V.</au><au>Hata, Jun‐ichi</au><au>Roald, Borghild</au><au>Dehner, Louis P.</au><au>Gerbing, Robert B.</au><au>Stram, Daniel O.</au><au>Lukens, John N.</au><au>Matthay, Katherine K.</au><au>Shimada, Hiroyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revision of the International Neuroblastoma Pathology Classification</atitle><jtitle>Cancer</jtitle><date>2003-11-15</date><risdate>2003</risdate><volume>98</volume><issue>10</issue><spage>2274</spage><epage>2281</epage><pages>2274-2281</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>BACKGROUND Ganglioneuroblastoma, nodular (GNBn) comprises one of the categories of peripheral neuroblastic tumors. All tumors in this category, according to the original International Neuroblastoma Pathology Classification, are classified into an unfavorable histology group. Subsequently, it has been reported that GNBn can be divided into two prognostic subsets, a favorable subset (FS) and an unfavorable subset (US). METHODS Histology slides from 70 patients who were enrolled in Children's Cancer Group studies 3881 and 3891 and who had a diagnosis of GNBn were reviewed jointly by the members of International Neuroblastoma Pathology Committee (INPC): 1) to confirm the diagnosis of GNBn, 2) to identify the FS and US by applying the same age‐linked criteria that were used to distinguish the favorable histology group and unfavorable histology group in conventional neuroblastoma tumors from the neuroblastomatous component of GNBn tumors, and 3) to verify the significant prognostic difference between these two subsets. The patients had been used in a previous study, and survival data for the patients were updated since the time of their last report. RESULTS The review clarified and illustrated morphologic characteristics of classical GNBn and it variants. The diagnosis of GNBn was confirmed in 67 of 70 patients. There were 22 patients with GNBn in the FS and 45 patients with GNBn in the US. The estimated survival differences between the FS and US patients with GNBn were statistically significant (8‐year event free survival rate: 86.1% vs. 32.2%; P = 0.0003; overall survival rate: 90.5% vs. 33.2%; P = 0.0003). CONCLUSIONS This study confirmed the recently defined prognostic subsets of GNBn. The INPC proposes to modify the International Neuroblastoma Pathology Classification by distinguishing the FS and the US among patients with GNBn tumors. Cancer 2003. © 2003 American Cancer Society. The International Neuroblastoma Pathology Committee (INPC) conducted a review of 70 tumors in the ganglioneuroblastoma, nodular (GNBn) category. After clearly defining morphologic characteristics of those tumors and completing a survival analysis, the INPC proposes to modify the International Neuroblastoma Pathology Classification for GNBn by distinguishing prognostic subsets, favorable and unfavorable, in this category.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/cncr.11773</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2003-11, Vol.98 (10), p.2274-2281
issn 0008-543X
1097-0142
language eng
recordid cdi_wiley_primary_10_1002_cncr_11773_CNCR11773
source Wiley Online Library Free Content; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects ganglioneuroblastoma
histology
international classification
International Neuroblastoma Pathology Committee
nodular
peripheral neuroblastic tumors
prognostic subsets
title Revision of the International Neuroblastoma Pathology Classification
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A54%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revision%20of%20the%20International%20Neuroblastoma%20Pathology%20Classification&rft.jtitle=Cancer&rft.au=Peuchmaur,%20Michel&rft.date=2003-11-15&rft.volume=98&rft.issue=10&rft.spage=2274&rft.epage=2281&rft.pages=2274-2281&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.11773&rft_dat=%3Cwiley%3ECNCR11773%3C/wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true